Research Mentor Name

Ira Winer

Research Mentor Email Address

iwiner@med.wayne.edu

Institution / Department

Division of Gynecologic Oncology, Karmanos Cancer Institute, Wayne State University

Document Type

Research Abstract

Research Type

womenshealth

Graduate Level Research

no

Abstract

Background:
The KELIM score, derived from CA-125 kinetics, reflects intrinsic tumor chemosensitivity in ovarian cancer. This retrospective study evaluated whether KELIM predicts clinical outcomes in patients receiving bevacizumab in a real-world setting.

Methods:
Twenty-four patients with advanced ovarian cancer treated with platinum-based chemotherapy and bevacizumab at a tertiary center in Detroit, MI, were included. KELIM scores were calculated from CA-125 values during the first 100 treatment days (www.biomarker-kinetics.org) and classified as favorable (≥1.0) or unfavorable (< 1.0). Progression-free survival (PFS) was measured from diagnosis to recurrence, and overall survival (OS) from diagnosis to last contact or death. Surgical outcomes, debulking approach, PARP inhibitor use, and survival status were analyzed descriptively.

Results:
Nineteen patients (79%) had favorable KELIM, and five (21%) had unfavorable KELIM. Compared to the favorable group, the unfavorable group had higher recurrence (100% vs. 58%), shorter median OS (17.9 vs. 23.0 months), and higher hospice or death rates (80% vs. 5%). None underwent primary debulking (0% vs. 32%), and PARP inhibitor use was lower (40% vs. 58%). Optimal or no gross cytoreduction was achieved in 11/19 favorable vs. 3/5 unfavorable patients.

Conclusion:
Unfavorable KELIM was associated with poorer survival, higher recurrence, and reduced surgical intervention. Despite limited sample size, results support KELIM as a potential marker of tumor biology and treatment response. Prospective studies with multivariate adjustment are warranted.

Disciplines

Medicine and Health Sciences | Obstetrics and Gynecology | Oncology

Download

Share

COinS